Dogwood Therapeutics (DWTX) Corporate presentation summary

Corporate overview and leadership

• Headquarters in Atlanta, GA, listed on Nasdaq with 33.99 million shares outstanding and $13.2 million in cash as of March 31, 2026.

• Executive team has a proven track record developing blockbuster pain medicines such as Celebrex, Lyrica, Savella, and Cimzia.

• Analyst coverage includes H.C. Wainwright and Maxim Group.

Unmet medical need and market opportunity

• Over 3 million US patients suffer from chemotherapy-induced neuropathic pain (CINP), with 7.5 million experiencing painful neuropathy.

• CINP market across US, EU4/UK, and Japan is valued at $1B, projected to reach $3B by 2036.

• No FDA-approved treatments for CINP; current therapies include SNRIs, opioids, and tricyclic antidepressants.

Lead asset: Halneuron® (Tetrodotoxin, TTX)

• Halneuron is a voltage-gated sodium channel blocker, specifically targeting NaV1.7, critical for pain signaling.

• Demonstrated statistically significant and durable pain reduction in cancer and chemotherapy-related pain studies.

• Administered as a subcutaneous injection, with no central nervous system effects.